Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
DEXAPOMA+ISAT
Cancer Type
Hematologic,
Multiple Myeloma
Intent
Palliative
Regimen Category
Evidence-Informed
Funding Program
New Drug Funding Program
Isatuximab - In Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Exceptional Access Program
pomalidomide - In combination with isatuximab and dexamethasone for relapsed and/or refractory multiple myeloma, according to specific criteria
ODB - General Benefit
dexamethasone
Drugs in Regimen
Regimen Monograph
Feb 2024
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: August 12, 2026
